Arcus says Nature study links casdatifan-driven EPO suppression to improved outcomes in advanced kidney cancer

Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

RCUS

0.00
  • Arcus reported Nature publication from ARC-20 linking casdatifan activity in metastatic clear cell renal cell carcinoma to HIF-2a biology.
  • Deeper suppression of serum EPO, a proposed biomarker of HIF-2a inhibition, correlated with higher response rates and longer progression-free survival.
  • At an Aug. 15, 2025 cutoff, confirmed ORR was 35% in the 100 mg once-daily tablet cohort; median PFS was not estimable.
  • Across four monotherapy cohorts (n=121), confirmed ORR was 31%; median PFS was 12.2 months.
  • Later analysis with a Jan. 30, 2026 cutoff showed median PFS of 15.1 months in the 100 mg once-daily cohort used in PEAK-1 Phase 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260701224768) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.